NCT06269978 2026-03-10
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
Clinical Trials
12 trialsNCT04587739 2025-12-23
KARCHER-1
University Hospital, Lille
Phase 1 Recruiting
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT05296005 2025-02-07
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03373188 2024-03-20
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
Emory University
Phase 1 Completed
NCT06281860 2024-02-28
PITHAC
Centre Hospitalier Universitaire Vaudois
Phase 1 Unknown
NCT02910843 2023-01-10
RECAP
Swiss Cancer Institute
Phase 1 Terminated
NCT01561014 2018-07-02
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Wake Forest University Health Sciences
Phase 1 Completed
NCT02598687 2016-04-21
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Maastricht Radiation Oncology
Phase 1 Withdrawn
NCT00543842 2015-02-26
Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00215956 2013-12-23
A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01456923 2011-10-21
Chemotherapy With DNA Damaging Agents In Colorectal Cancer
Centro Hospitalar Nordeste
Phase 1 Completed